Enopace Biomedical is developing a device to treat patients with heart failure.

The company's technology comprises a minimally invasive, implantable neurostimulation device designed to increase cardiac efficiency by reducing left-ventricular workload.The company's Harmony™ System was designed for heart failure patients and is a minimally invasive neuromodulation implant supplies precise and personalized aortic stimulation, while the wearable unit allows the user to switch the therapy on or off, as needed.

The Harmony System can be implanted in 30 minutes in a standard catheterization procedure, without the need for general anesthesia.